NVO earnings: real EPS beat/miss history, analyst consensus Buy, P/E 11.33. Updated 2026-07-23.
Novo Nordisk (NVO) Research Hub
Novo Nordisk (NVO) trades on NYSE, DK in the Healthcare (Drug Manufacturers - General) sector. As of 2026-09-11, shares last closed at 43.07 USD (-3.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 11.33, market cap 214.97B. This hub links to the full technical, earnings and options research available for NVO.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - General) |
|---|---|
| Exchange | NYSE, DK |
| Last close | 43.07 USD (-3.34%) |
| 52-week range | 42.722 USD – 52.12 USD |
| Trend regime | Range |
| 14-day RSI | 37.3 (Bearish) |
| Trailing P/E | 11.33 |
| Market cap | 214.97B |
| Dividend yield | 3.76% |
Available research for NVO
Covered Call on NVO: how it works, illustrative setup around the real 43.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NVO: how it works, illustrative setup around the real 43.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NVO: how it works, illustrative setup around the real 43.07 USD price, max profit/loss, breakeven and when to use it. Educational.
NVO technical analysis: range, last 43.07 USD, RSI 37.3, 52w range 42.722 USD–52.12 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NVO in?
Novo Nordisk (NVO) is classified under Healthcare (Drug Manufacturers - General), listed on NYSE, DK.
Is NVO in an uptrend or downtrend?
As of 2026-09-11, NVO is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NVO's trailing P/E ratio?
NVO's trailing P/E is 11.33, with a market cap of 214.97B. See the earnings research page for full valuation detail.